Intismeran Autogene
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Intismeran Autogene, covering 2025-09-02 to 2026-04-23. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) [Phase 3]